Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Comparing the Big 3, Semaglutide, Tirzepatide and Retatrutide : r Mounjaro CagriSema vs Tirzepatide: Head to Head Obesity Trial Results Yasir Zaroug posted on the topic LinkedIn Cagrilintide and semaglutide together drive record weight loss in global trial